Carbonic anhydrase‐9‐targeted near‐infrared photoimmunotherapy as a theranostic modality for clear cell renal cell carcinoma
International Journal of Cancer · 2025
DOI: 10.1002/ijc.35364 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, 2025. Verfasst von Hiroshi Fukushima und 13 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Carbonic Anhydrase IX, Kidney Neoplasms, Immunotherapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Intramural NIH HHS, NCI NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Carbonic anhydrase‐9 (CA9) is highly expressed in clear cell renal cell carcinoma (ccRCC) cells despite no expression in normal kidney tissues. Thus, CA9 has been proposed as a theranostic target for radioligand therapy (RLT). However, ccRCC tends to be radioresistant and may not effectively respond to RLT. Alternatively, CA9 can be targeted for near‐infrared photoimmunotherapy (NIR‐PIT) of ccRCC. Here, we sought to test NIR‐PIT using CA9 in a preclinical model of ccRCC to determine its potential as a therapeutic strategy. Tissue microarray analysis showed that membrane CA9 was expressed in the majority of ccRCC cases. In vitro, CA9‐targeted NIR‐PIT induced cell membrane damage and cell killing in all CA9‐expressing ccRCC cell lines specifically, UOK154, UOK220, and UOK122. In vivo, CA9‐targeted NIR‐PIT significantly inhibited tumor growth and prolonged survival in UOK154 and UOK220 subcutaneous xenograft models. Notably, 70%–80% of mice achieved complete remission after a single treatment of NIR‐PIT. Additionally, remaining tumors after the first NIR‐PIT persistently expressed CA9, suggesting that remaining tumors can be treated with repeated NIR‐PIT. Furthermore, CA9‐targeted NIR‐PIT induced significant cytoplasmic damages on ccRCC cells in UOK154 orthotopic xenograft models. In conclusion, CA9‐targeted NIR‐PIT, which allow for safe and repeated application on the same lesion, is a promising treatment for ccRCC, especially in the management of multiple primary ccRCC (e.g., von Hippel–Lindau syndrome) and oligometastatic ccRCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, USA.
- Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, USA.
ORCID-Profile: Hiroshi Fukushima, Hisataka Kobayashi
Förderung
- Intramural NIH HHS
- NCI NIH HHS
- National Cancer Institute
Zitieren
APA
Fukushima, H., Takao, S., Furusawa, A., Suzuki, M., Yang, Y., Ricketts, C. J., Kano, M., Okuyama, S., Yamamoto, H., Kano, M., Ball, M. W., Choyke, P. L., Linehan, W. M., & Kobayashi, H. (2025). Carbonic anhydrase‐9‐targeted near‐infrared photoimmunotherapy as a theranostic modality for clear cell renal cell carcinoma. International Journal of Cancer. https://doi.org/10.1002/ijc.35364
Vancouver
Fukushima H, Takao S, Furusawa A, Suzuki M, Yang Y, Ricketts CJ, et al. Carbonic anhydrase‐9‐targeted near‐infrared photoimmunotherapy as a theranostic modality for clear cell renal cell carcinoma. International Journal of Cancer. 2025. doi:10.1002/ijc.35364
BibTeX
@article{Fukushima2025,
author = {Fukushima, Hiroshi and Takao, Seiichiro and Furusawa, Aki and Suzuki, Motofumi and Yang, Youfeng and Ricketts, Christopher J and Kano, Makoto and Okuyama, Shuhei and Yamamoto, Hiroshi and Kano, Miyu and Ball, Mark W and Choyke, Peter L and Linehan, W Marston and Kobayashi, Hisataka},
title = {Carbonic anhydrase‐9‐targeted near‐infrared photoimmunotherapy as a theranostic modality for clear cell renal cell carcinoma},
journal = {International Journal of Cancer},
year = {2025},
doi = {10.1002/ijc.35364}
}
EUVIMED